Informations de référence uniquement. Demandez toujours conseil à un professionnel de santé.
MPMediPriceHubRéférence des prix des médicaments
PRODUCT INFORMATION

Vosevi 400/100/100mg Filmtabletten,1 x 28 (sofosbuvir/velpatasvir/voxilaprevir,SOF)

sofosbuvir/velpatasvir/voxilaprevir,SOF

Vosevi 400/100/100mg Filmtabletten,1 x 28 (sofosbuvir/velpatasvir/voxilaprevir,SOF)
Reference priceEUR €185.15Original source price: INR 16,831.76. Converted estimates are available by currency selection.
BrandVosevi
ManufacturerGilead Sciences GmbH
Prescription requiredYes

Description

Vosevi 400/100/100mg Filmtabletten,1 x 28(/ /) (sofosbuvir/velpatasvir/voxilaprevir,SOF) is a medicine catalog record in the MediPriceHub database. Active ingredient: sofosbuvir/velpatasvir/voxilaprevir,SOF. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Gilead Sciences GmbH. Therapeutic category: Medicine Library > Liver and Gallbladder Diseases > Hepatitis C drugs. Pack information: 400 / 100 / 10 28. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration and Clinical Studies ]: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.

How to Use

Use sofosbuvir/velpatasvir/voxilaprevir,SOF under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: sofosbuvir/velpatasvir/voxilaprevir,SOF. Pack size: 400 / 100 / 10 28. Pack unit: bottle. Manufacturer: Gilead Sciences GmbH. Origin country: Germany. Source category: Medicine Library > Liver and Gallbladder Diseases > Hepatitis C drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Anti-infective medicines may cause nausea, diarrhea, abdominal discomfort, headache, rash, allergic reactions, liver enzyme changes, interactions with other medicines, or organism-specific resistance concerns. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

Ces informations sont fournies à titre indicatif. Demandez conseil à un professionnel de santé avant d'utiliser un médicament.